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ABSTRACT
Prolactin promotes a variety of cancers by an array of different mechanisms. 
Here, we have investigated prolactin’s inhibitory effect on expression of the cell 
cycle-regulating protein, p21. Using a miRNA array, we identified a number of miRNAs 
upregulated by prolactin treatment, but one in particular that was strongly induced 
by prolactin and predicted to bind to the 3′UTR of p21 mRNA, miR-106b. By creating 
a p21 mRNA 3′UTR-luciferase mRNA construct, we demonstrated degradation of the 
construct in response to prolactin in human breast, prostate and ovarian cancer cell 
lines. Increased expression of miR-106b replicated, and anti-miR-106b counteracted, 
the effects of prolactin on degradation of the 3′UTR construct, p21 mRNA levels, 
and cell proliferation in breast (T47D) and prostate (PC3) cancer cells. Increased 
expression of miR-106b also stimulated migration of the very epithelioid T47D cell line. 
By contrast, anti-miR-106b dramatically decreased expression of the mesenchymal 
markers, SNAIL-2, TWIST-2, VIMENTIN, and FIBRONECTIN. Using signaling pathway 
inhibitors and the 3′UTR construct, induction of miR-106b by prolactin was determined 
to be mediated through the MAPK/ERK and PI3K/Akt pathways and not through Jak2/
Stat5 in both T47D and PC3 cells. Prolactin activation of MAPK/ERK and PI3K/Akt also 
activates ERα in the absence of an ERα ligand. 17β-estradiol promoted degradation 
of the construct in both cell lines and pre-incubation in the estrogen antagonist, 
Fulvestrant, blocked the ability of both prolactin and 17β-estradiol to induce the 
construct-degrading activity. Together, these data support a convergence of the 
prolactin and 17β-estradiol miR-106b-elevating signaling pathways at ERα. 
INTRODUCTION
Prolactin is a peptide hormone produced and 
released from many tissues, but in largest quantity 
from the pituitary gland [1]. The best known functions 
of prolactin are in the mammary gland where prolactin 
promotes gland development during pregnancy, the 
synthesis of milk, and maintenance of milk secretion [2]. 
However, prolactin also functions in immune regulation 
[3–5], adipocyte differentiation [6, 7], islet proliferation 
[8, 9] and regulation of bone density [10, 11]. In addition, 
more and more evidence has accumulated indicating that 
prolactin promotes tumorigenesis in various types of 
cancers, including breast [12–14], prostate [14, 15], ovary 
[14, 16], liver [17], and brain [18], as well as stimulating 
the growth of pituitary tumors [19, 20]. One of the tumor-
promoting mechanisms is decreased expression of the 
cell cycle inhibitor CDKN1A, also known as p21 [14]. A 
reduction in p21 expression may have a direct effect on cell 
proliferation, but may also contribute to anti-estrogen and 
other drug resistance in some cancers [21–26]. As might 
be expected, the expression of p21 is tightly regulated by 
several molecules, including p53 [27], BRCA1 [14, 28], 
TGF-β [29], RAR/RXR [30] and the vitamin D receptor 
[31]. In addition to expression of p21, cellular localization 
of p21 is also related to the therapeutic resistance [32]. 
Restriction of p21 to the cytosol is regulated through 
post-translational modification on threonine 145, which 
is phosphorylated by Akt, PKA or pim-1 kinase [32–34]. 
Therefore, regulation of p21 expression and localization is 
of importance in both cancer development and therapeutic 
resistance. 
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Estrogens also contribute to progression of a number 
of cancers [35–38] . We and others have identified a 
synergy between prolactin and estrogen in the promotion 
of breast cancer [39–42], and the ability of prolactin to 
activate the estrogen receptor α (ERα) in the absence of an 
ERα ligand [40, 41]. Thus, studying the interplay between 
these two hormones in cancer progression is important. 
We have previously demonstrated that prolactin 
regulates p21 transcription through inhibition of BRCA1 
function [14]. In the current study, we have determined 
the existence of an additional mechanism through which 
prolactin decreases the amount of p21, the induction of 
miR-106b, a mechanism duplicated by estradiol. Further, 
that increased expression of miR-106b causes increased 
cell number and enhanced migratory capacity. 
RESULTS
Prolactin effects on miRNA expression
To explore how prolactin might reduce expression 
of p21 mRNA, we performed a miRNA microarray in 
T-47D breast cancer cells. To help refine our analysis, 
we used both prolactin, which reduces, and the selective 
prolactin receptor modulator, S179DPRL, which elevates, 
p21 [14, 43]. Prolactin and S179DPRL bind to the same 
receptors [44], and have some functions in common [45], 
but in regard to cell proliferation, prolactin stimulates [46], 
while S179DPRL inhibits (14, 43, 45, 46). Using a 2-fold 
change in expression as our stringency cutoff, there were 
21 miRNAs upregulated by prolactin (Table 1). Among 
these miRNAs, miR-106b has been shown to target 
to the 3′ UTR of p21 mRNA directly [47]. None of the 
other 20 miRNAs upregulated by prolactin is predicted 
to interact directly with any region of p21 mRNA using 
online database miRDB analysis [48, 49]. Most these other 
miRNAs have been reported to be associated with reduced 
expression of p21 indirectly [50–52]. miR-107, miR-153 
and miR-142-3p indirectly reduce p21 expression through 
targeting the upstream regulators, FOXO1, PTEN and 
FOXO4, respectively [50–52]. We therefore focused 
further analysis on miR-106b. Consistent with a p21-
elevating effect of S179DPRL [46], S179DPRL also 
decreased expression of miR106b by 43% compared to 
the PBS control (Figure 1 A). 
To substantiate a role for miRNA in the degradation 
of p21 mRNA in the current study, we created a plasmid 
construct by conjugating the 3′UTR of p21 mRNA 
downstream of a luciferase reporter. If there were miRNAs 
targeted to the 3′UTR, this would lead to degradation of 
luciferase mRNA and therefore would reduce translated 
luciferase activity (Figure 1B). Consistent with the 
microarray experiment, when T-47D cells were transfected 
with this plasmid and treated with prolactin or vehicle for 
72 hours, treatment with prolactin significantly reduced 
the luciferase activity (Figure 1C). In addition to T-47D 
cells, this effect was also reproduced in human prostate 
cancer PC3 cells (Figure 1D). To further illustrate this 
was not limited to the 2 cell types we focused on for 
most of the study, we also examined a second human 
breast cancer cell line, MCF-7, and 3 human ovarian 
cancer cell lines. For these additional cell lines the effect 
of prolactin on luciferase activity is shown at 24 hours 
in Figure 1E–1H. Prolactin caused a significant reduction 
in luciferase activity in MCF-7, TOV-112D, and OV 90 
cells in this time frame, indicating prolactin induction of 
miRNA targeted to the 3′UTR of p21 mRNA. The degree 
of response was very cell line dependent, ranging from a 
15% reduction of luciferase activity in MCF7 cells to an 
80% reduction in TOV-112D cells. 
To demonstrate that the effect of prolactin was 
mediated through miR-106b, we constructed shRNA 
plasmids to be used to increase expression of either 
miR-106b or anti-miR-106b. Increased expression of miR-
106b essentially eliminated p21 mRNA in T47D cells, 
whereas anti-miR-106b increased p21 mRNA. In PC3 
cells, which grow more rapidly and are less epithelioid, 
increased expression of miR106b had no effect, while 
increased expression of anti-miR106b quadrupled the 
expression of p21 mRNA (Figure 2A and 2B). Using 
the luciferase assay to assess the effect of increased 
expression with and without prolactin, increased 
expression of miR-106b reduced luciferase activity and 
prolactin treatment did not augment this effect. However, 
the luciferase-lowering effect of prolactin was blocked 
when there was increased expression of anti-miR-106b 
(Figure 2C and 2D). Collectively, these results show 
that prolactin induced the production of miR-106b 
and that this then targeted the 3′ UTR of p21 mRNA. 
Cells expressing more miR-106b were more 
aggressive 
To determine the outcome of upregulation of 
miR-106b in cancer, we first examined effects on relative 
cell number, as assessed by MTS assay, with increased 
expression of miR-106b or anti-miR106b in the absence 
or presence of prolactin. As seen in Figure 3A, increased 
expression of miR-106b or anti-miR106b in T47D cells 
did not cause any effect on cell number in the absence 
of prolactin. Prolactin alone (with control shRNA) 
increased the relative number of cells by 35% during the 
72-hour incubation. Additional expression of miR-106b 
in the presence of prolactin doubled the response. By 
contrast, increased expression of anti-miR-106b in the 
presence of prolactin decreased cell number below that 
without prolactin. In the PC3 cell line, which grows 
rapidly, increased expression of miR-106b or incubation 
with prolactin did not significantly increase cell number. 
However, increased expression of anti-miR-106b 
significantly inhibited growth of cells in the presence of 
prolactin (Figure 3B). These results suggest that increased 
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levels of miR-106b alone are insufficient to cause an 
increase in cell number, but that by reducing p21 levels, 
any promotion of proliferation can be enhanced. By 
contrast, increased levels of anti-miR-106b effectively 
block proliferation.
We next examined whether increased expression of 
miR-106b affected cell migration. T-47D cells were chosen 
for this analysis because they are very epithelioid in nature 
and migration rates are normally very slow. Cells were 
seeded in a constrained area in the center of the well and 
then transfected with control shRNA or miR-106b shRNA 
plasmid. As seen in Figure 3C, most control shRNA-
transfected cells remained in the original area. However, 
cells with increased expression of miR-106b dispersed 
to a greater radius. Incubation in prolactin (with control 
shRNA), had a similar effect to transfection with miR-106b 
shRNA (compare Figure 3C and 3D). However, combining 
increased expression of miR-106b with incubation in 
prolactin did not further increase the amount of migration. 
As would be predicted from these results, expression of 
anti-miR-106b decreased migration to about the level 
seen in the absence of prolactin and additional miR-106b, 
thereby confirming a role for miR-106b in the promotion 
of migration.
To further confirm an effect on migratory capacity, 
we examined the expression of genes characteristic 
of an epithelial to mesenchymal transition. Increased 
expression of miR-106b with prolactin treatment in T47D 
cells increased expression of fibronectin and vimentin, 
whereas increased expression of anti-miR-106b along with 
prolactin treatment decreased the expression of fibronectin, 
vimentin, twist2 and snail2, with the last reduced to 
undetectable levels, leaving us no ability to determine 
significance levels (Figure 3E–3H). Taken together, these 
results suggest a high impact of miR-106b on proliferative 
and metastatic aspects of tumor progression.
The induction of miRNAs by prolactin was 
mediated through MAPK, PI3K and activation 
of the estrogen receptor
To identify which prolactin signaling pathway/s 
contributed to the induction of the miRNA(s), PC3 and 
T-47D cells were pre-treated with different signaling 
inhibitors (PD98059 for MAPK/ERK, Wortmannin for 
PI3K/Akt, AG490 for Jak2/Stat5) and transfected with 
the luciferase-p21 3′ UTR plasmid. The effect of these 
inhibitors was also validated by examining activation of 
the appropriate signaling molecules using Western blot 
(data not shown). Because these inhibitors negatively 
impact cell viability when used for extended periods, 
effects on luciferase activity were measured 24 hours 
Table 1: Upregulated miRNAs (> 2 fold) by prolactin
miRNA Fold
miR-10b-5p 2.648065866
miR-95-3p 2.365516801
miR-92-3p 2.278490033
miR-92b-3p 2.26453033
miR-27a-3p 2.250477655
miR-26b-5p 2.225025659
miR-17-3p 2.210714719
miR-215-5p 2.196169084
miR-101-1-3p 2.173145188
miR-30a-3p 2.164483133
miR-142-5p 2.154083454
miR-214-3p 2.127021904
miR-132-3p 2.100969166
miR-142-3p 2.097205532
miR-185-5p 2.090877882
miR-153-3p 2.047451196
miR-372-3p 2.029475511
miR-186-5p 2.011486344
miR-103-3p 2.006442321
miR-107 2.000847941
miR-106b-5p 2.000066166
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after transfection and incubation with the inhibitors, with 
20 of those hours in the absence or presence of prolactin. 
This protocol was sufficient for all inhibitors except 
wortmannin, which still had a small effect (~20% in both 
the absence and presence of prolactin) on cell viability in 
the 24 hour time frame (data not shown). To compensate, 
data are expressed as a percent of luciferase activity in the 
absence of prolactin. i.e. the graph is specifically showing 
the effect of the inhibitors on the induction of p21-targeting 
miRNA as a function of prolactin treatment. Given that 
we are looking at increases in luciferase activity if the 
signaling pathway is blocked, an increase in translated and 
active luciferase is unlikely to be the result of a decrease 
in cell viability. While one tends to think of the Jak2/
Stat5 pathway as being of primary importance to prolactin 
signaling, AG490 had no effect on the induction of 
miRNA by prolactin. However, prolactin failed to reduce 
luciferase activity when PD98059 or wortmannin was 
present in the medium (Figure 4A in T47D cells and 4B 
in PC3 cells). Thus, prolactin signals through MAPK/ERK 
and PI3K/Akt to elevate miRNA targeting the p21 mRNA 
3′UTR. Wortmannin is a more potent PI3K/Akt inhibitor 
than the commonly used LY294002. However, at higher 
concentrations, wortmannin may also inhibit other PI3 
related kinases such as mTOR, DNA-PK, and ATM [53]. 
As the concentration we used may also block these other 
kinases, we therefore cannot exclude the possibility that 
these other kinases might also be involved in the miRNA 
production.
Prolactin signaling through MAPK/ERK and PI3K/
Akt pathways also activates ERα in the absence of an 
ERα ligand [40]. We therefore examined the potential role 
for activated ERα in the production of miR-106b. Cells 
were pre-treated with the ERα inhibitor, ICI-182780, and 
then transfected with the luciferase-p21 3′UTR plasmid. 
As seen in Figure 4C and 4D, addition of ICI-182780 
not only blocked the luciferase degradation promoted 
by prolactin, but also increased the amount of luciferase 
activity compared to control. In other words, blockade/
degradation of ERα inhibited the ability of prolactin to 
elevate the miRNA in both breast cancer and prostate 
cancer cell lines. 
To further demonstrate that activation of ERα can 
result in the production of miRNA targeting the p21 
Figure 1: Prolactin treatment induced miR-106b targeted to the 3′UTR of the p21 in cancers. (A) T47D cells were treated 
with vehicle control, 100 ng/mL prolactin or 100 ng/mL selective prolactin receptor modulator, S179DPRL, for 72 hours. Total RNA was 
extracted and 5 µg total RNA from each treatment was subjected to miRNA array. (B) Illustration of luciferase-3′UTR assay to detect 
miRNA production. When there was miRNA production that bound to the 3′UTR region, this would lead to degradation of luciferase 
mRNA and reduced luciferase signals. The breast cancer cell line, T47D (C) and prostate cancer cell line, PC3 cells (D) were transfected 
with luciferase-p21 mRNA 3′UTR plasmid followed by 100 ng/mL prolactin treatment for 72 hours. This analysis was also performed 
in one additional breast cancer cell line, MCF7 (E) and 3 ovarian cancer cell lines, TOV-112D (F), OV-90 (G) and TOV-21G (H) with 
prolactin treatment limited to a 24 hour period in these cases. Luciferase activity was then measured. Each luciferase activity value from 
vehicle-treated cells was set as 100. Data are presented as the mean ± S.D.; *P < 0.05 and **P < 0.01 (compared with vehicle treatment). 
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mRNA 3′UTR, cells were transfected with the luciferase 
construct and treated with 17β-estradiol. As seen in 
Figure 5A and 5B, estradiol induces miRNAs targeting the 
3′UTR of p21 mRNA in both breast cancer and prostate 
cancer cell lines. In addition, when cells were pretreated 
with ICI-182780, the reduction of luciferase activity by 
estradiol was relieved (Figure 5C and 5D). 
Taken together, these data indicate that activated 
ERα mediates the effect of both prolactin and estradiol 
on the production of miRNA targeting the 3′UTR of the 
p21 mRNA. 
DISCUSSION
There are many publications supporting roles 
for prolactin in the progression of a variety of cancers 
[13, 16, 54–56]. These include various pro-proliferative, 
anti-apoptotic and pro-metastatic roles. In addition, 
prolactin may contribute to therapeutic drug resistance 
[57, 58]. The development of resistance to therapy 
can occur by a variety of mechanisms, but loss of p21 
expression is a common factor [21, 23–26]. Identification 
of mechanisms governing p21 expression may lead to 
Figure 2: Inhibition of miR-106b by anti-miR106b shRNA blocked prolactin mediated effect on both the 3′UTR 
of p21 mRNA and p21 mRNA expression. Increased expression of miR-106b shRNA reduced p21 mRNA in T47D cells 
(A) while increased expression of anti-miR-106b shRNA resulted in more p21 mRNA in PC3 cells (B). The expression of p21 transcript 
was normalized to GAPDH. Each transcript level from non-treated cells was set as 1. Both T47D (C) and PC3 (D) cells were co-transfected 
with luciferase-p21 3′UTR plasmid and control shRNA/ miR-106b shRNA/ anti-miR-106b shRNA and treated with 100 ng/mL prolactin or 
vehicle for 72 hours. Luciferase activity was then measured. Each luciferase activity value from vehicle treated cells was set as 100. Data 
are presented as mean ± S.D.; *P < 0.05 and **P < 0.01 (compared with vehicle treatment).
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development of new therapeutics, as well as to strategies 
to prevent development of resistance to current therapies. 
To explore how prolactin might reduce expression 
of p21 mRNA, we performed a miRNA microarray in 
T-47D breast cancer cells. Using a 2-fold change as the 
stringency cutoff, 21 miRNAs were upregulated by 
prolactin. To help sort through which of these to focus 
on, we used two approaches. The first approach was to 
compare with the effect of S179DPRL. While prolactin 
decreases expression of p21, S179DPRL increases p21 
[14, 43]. Although the mechanism for increasing p21 
might not have been through decreased production of 
miRNAs, we could at least expect to be able to eliminate 
some miRNAs from further consideration if they were also 
increased by S179DPRL. miR-9-1-5p is a good example 
of one eliminated. The second approach was to examine 
these 21 miRNAs for predicted direct interactions with 
any region of p21 mRNA by online database miRDB 
search [48, 49]. miR-106b was the only predicted miRNA 
and had been shown to interact with p21 mRNA directly 
[47], although its role as a mediator of any of prolactin’s 
functions had not been described. For the remaining 
20 miRNAs, literature suggested an indirect regulation 
on p21 expression. For example, miR-107, miR-153, and 
miR-142-3p had been shown to reduce p21 expression 
through targeting the upstream regulators, FOXO1, PTEN 
Figure 3: Effect of miR-106b on cell number, cell migration and mesenchymal gene expression. 10,000 T47D (A) and PC3 
(B) cells were transfected with control shRNA, miR-106b shRNA or anti-miR-106b shRNA plasmid and treated with vehicle (left panel) or 
100 ng/mL prolactin (right panel) for 72 hours. Relative cell number was then measured by MTS assay. Data are presented as the mean ± S.D.; 
*P < 0.05. T47D cells were seeded in the constrained area and transfected with control shRNA or miR-106b shRNA plasmid in the 
absence (C) or presence (D) of prolactin. After 72 hours, the distribution of cells was counted in both the original seeded area and outside 
this area. (E–H). T47D cells were transfected with control shRNA, miR-106b shRNA or anti-miR-106b shRNA plasmid in the presence 
of 100 ng/mL prolactin for 72 hours. The expression of mesenchymal genes was analyzed by real time PCR. The expression of transcript 
was normalized to GAPDH. Each transcript level from control shRNA transfected cells was set as 1. Data are presented as mean ± S.D.; 
*P < 0.05 and **P < 0.01 (compared with control shRNA transfection).
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and FOXO4, respectively [50–52]. Our focus was then on 
miR-106b. miR-106b was not only increased by prolactin, 
but decreased by S179DPRL, suggesting in fact that at 
least part of the mechanism used by S179DPRL to elevate 
p21 is a reduction in miR-106b. 
Using the artificial construct, the data presented 
show that prolactin stimulates the production of a miRNA 
that targets the 3′ UTR of p21 mRNA and that this is 
duplicated by increased expression of miR-106b and 
antagonized by anti-miR-106b. Furthermore, that the 
effects of miR-106b and anti-miR106b in the luciferase 
assay are translated to effects on levels of p21 mRNA. In 
T47D cells, increased expression of miR-106b essentially 
eliminated p21 mRNA, while anti-miR-106b had little 
Figure 4: Prolactin activation of MAPK/ERK, PI3/Akt and ERα are involved in miRNA induction targeted to the 
3′UTR of p21 mRNA. T47D (A) and PC3 cells (B) were transfected with the luciferase-p21 3′UTR plasmid and pre-treated with 
DMSO (control), 10 μM AG490, 20 μM PD98059 or 1 μM Wortmannin for 4 hours prior to the addition of 100 ng/mL prolactin or vehicle 
for 20 hours. Luciferase activity was then measured. Both T47D (C) and PC3 (D) cells were transfected with the luciferase-p21 3′UTR 
plasmid and treated with DMSO control (left panel) or 10 nM ICI-182780 (right panel) in the presence of 100 ng/mL prolactin for 20 hours. 
Luciferase activity was then measured. Each luciferase activity value from vehicle-treated cells was set as 100. Data are presented as 
mean ± S.D.; *P < 0.05 and **P < 0.01 (compared with vehicle treatment).
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effect. By contrast, miR-106b had little effect on p21 
mRNA in PC3 cells, while anti-miR-106b quadrupled 
the amount of p21 mRNA. These results are consistent 
with different baseline levels of p21 in the two cell lines, 
with levels of p21 higher in the slower growing and more 
epithelioid T47D cell line. However, the amount of p21 
mRNA did not translate to a change in cell number unless 
prolactin was also present. Thus, prolactin has additional 
functions that affect cell number beyond those mediated 
by miR-106b. To this point, in a previous publication [14] 
we demonstrated that prolactin regulates transcription of 
the p21 gene by interfering with BRCA1 transactivation. 
Therefore, in response to prolactin, one might expect a 
greater reduction in p21 and a greater effect on cell number 
than that brought about only by increased expression of 
miR-106b. Alternatively, a greater effect of prolactin on 
cell number versus that produced by increased expression 
of miR-106b might be expected as a result of prolactin’s 
ability to stimulate the cell cycle [59, 60]. Given the ability 
of increased miR-106b to reduce p21 mRNA to essentially 
zero (albeit mRNA and not protein) and that this does not 
cause an increase in cell number, the most likely of these 
two explanations is that the additional effect of prolactin 
is pro-proliferative rather than anti-apoptotic. 
Figure 5: Activation of ERα by 17β-estradiol significantly induced miRNA production that bound to the 3′UTR of 
the p21 mRNA construct. T47D (A) and PC3 cells (B) were transfected with the luciferase-p21 3′UTR plasmid followed by 1 nM 
17β-estradiol treatment. Luciferase activity was then measured after 72 hours. Both T47D (C) and PC3 (D) cells were transfected with 
the luciferase-p21 3′UTR plasmid and treated with DMSO control (left panel) or 10 nM ICI-182780 (right panel) in the presence of 1 nM 
17β-estradiol for 20 hours. Luciferase activity was then measured. Each luciferase activity value from vehicle-treated cells was set as 100. 
Data are presented as mean ± S.D.; *P < 0.05 and **P < 0.01 (compared with vehicle treatment).
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In addition to oncogenic miR-106b, prolactin also 
upregulated other oncomirs such as members of the 
miR-17/92 family. Interestingly, the only 2 miRNAs 
downregulated by prolactin, miR-219 and miR-31, exhibit 
antitumor effects [61–63]. These data are supportive of 
multiple tumorigenic roles for prolactin.
In addition to miR-106b, miR-106a was also induced 
by prolactin (1.5 fold), but to a level below the stringency 
of our microarray analysis. This miRNA is known to 
directly target the 3′UTR of p21. Therefore, the effect 
of prolactin to decrease p21 mRNA could be regulated 
by both miR-106b and miR-106a, but, based on relative 
expression levels, the contribution from miR-106a is less. 
The data also demonstrate that increased expression 
of miR-106b contributes to cell migration, which is 
consistent with previous studies by others. For example, 
Gong et al. [64] and Yau et al. [65] showed increased 
metastasis and migration in breast and hepatocellular 
carcinoma cells, respectively, with increased expression of 
miR-106b. Furthermore, induction of miR-106b is found 
in multiple types of cancers, including breast, prostate 
and ovarian cancers [66–69]. Prolactin also increases 
metastatic spread [55, 56], and the current experiments 
suggest that some of this may be through induction of 
miR-106b, although this was not directly addressed. 
Rather, we showed that prolactin induced miR106b, and 
miR-106b in turn increased expression of fibronectin and 
vimentin, while anti-miR-106b decreased expression of 
fibronectin, vimentin, twist2 and snail2. As p21 has been 
demonstrated to be an important inhibitor of the epithelial-
to-mesenchymal transition [70, 71], our data are consistent 
with the literature. 
There are other reported targets for miR-106b, such 
as PTEN, SMAD7 and REST [72–75] and downregulation 
of these targets by miR-106b also contributes to tumor 
progression. For instance, a decreased PTEN level would 
also cause reduced p21, and decreased SMAD-7 would 
lead to increased epithelial to mesenchymal transition 
[72, 75]. Thus, there are likely multiple integrated effects. 
When looking at an effect of prolactin, one might 
expect it to be related to the level of expression of prolactin 
receptors. We did see a wide range of responsiveness to 
prolactin in the luciferase assay and to some extent there 
is a correlation. For example, in the three ovarian cancer 
cell lines, expression of total prolactin receptor is high in 
TOV-112D, modest in OV-90 and low in the TOV-21G 
[16]. This pattern is consistent with the miRNA production 
by prolactin stimulation in these three cell lines. In addition, 
T-47D cells express more prolactin receptors than MCF-7 
cells [76] and T47D cells showed a greater response 
than MCF7 cells. However, PC3 cells have few prolactin 
receptors and yet showed a substantial response to prolactin 
in the luciferase assay. There must therefore be other factors 
at play governing this particular response to prolactin. 
One possible factor may be the status of p53. Under 
most conditions, p21 expression is p53 dependent [27]. 
Consistent with this suggestion, the cell lines with wild type 
p53, MCF-7 and TOV-21G cells, have lower induction of 
miR-106b by prolactin, while cell lines with mutant p53, 
TOV-112D, OV-90 and T47D, or with null p53, PC3, 
showed greater induction of miR-106b by prolactin. 
We have previously shown that prolactin activation 
of Stat5 causes it to form a complex with BRCA1 that 
prevents BRCA1 from transactivating the p21 promoter 
[14]. We therefore expected the Jak2/Stat5 signaling 
pathway to be involved in the production of miR-106b 
since both actions lead to reduced p21. However, based 
on the use of signaling pathway inhibitors, Jak2 is not 
involved. Rather, signaling from the prolactin receptor to 
increased expression of miR-106b is through MAPK/ERK 
and PI3K/Akt. Thus, multiple signaling pathways regulate 
p21 levels. These pathways are also activated by membrane 
ERα [77]. We therefore considered the possibility that 
there may be crosstalk and possible synergies between 
estradiol and prolactin signaling in the production of 
miR-106b, especially since there is synergy in terms of cell 
proliferation [40]. However, even though both estradiol 
and prolactin had similar effects in the luciferase assay, 
blockade/degradation of ERα blocked both the prolactin 
and estradiol effects, thereby demonstrating that ERα is 
situated between prolactin signaling and the production of 
miR-106b. How then does prolactin elevate expression of 
miR-106b? Interestingly, we have also previously shown 
that prolactin activation of the MAPK/ERK and PI3K/
Akt pathways leads to serine-118 phosphorylation of 
ERα and its activation in the absence of an ERα ligand 
[40]. Thus, even when the use of aromatase inhibitors 
deprives a patient of estradiol, prolactin would still be 
capable of reducing expression of p21 and promoting 
tumor progression, although prolactin expression would 
also usually be reduced with aromatase inhibitors [78, 79]. 
However, other positive influences on prolactin production 
such as stress [80] and the use of some anti-psychotics [81, 
82] would still be operative and capable of influencing 
tumor promotion through this mechanism.
In the current study, we have determined that 
upregulation of miR-106b by prolactin likely contributes 
to tumor malignancy. This upregulation is mediated 
through the Akt and MAPK pathways and the downstream 
activation of ERα. This is diagrammed in Figure 6. 
Thus, miR-106b or its regulated events might serve as 
therapeutic targets for both breast and prostate cancers.
MATERIALS AND METHODS
Cell culture
All cell lines (human breast cancer cell lines, T47D 
and MCF-7, the human prostate cancer cell line, PC3, and 
human ovarian cancer cell lines, TOV-112D, OV-90 and 
TOV-21G) were freshly purchased from ATCC (Manassas, 
USA) where they were authenticated utilizing Short 
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Tandem Repeat analysis. Cells were routinely cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS) and were used for experiments with passage 
numbers < 20. 
Production of reporter construct and pMIR 
luciferase assay
The 3′UTR fragment of p21 was first amplified 
using the primer pair in Table 2. The amplified fragment 
was digested with MluI /HindIII and then ligated to the 
pMIR reporter vector with the same restriction enzyme 
digestion (Applied Biosystems, Waltham, USA) using 
T4 DNA ligase (New England Biolabs, Ipswich, USA). 
Two hundred and fifty thousand cancer cells were seeded 
in each well of a 12-well plate and co-transfected with 
the luciferase-p21 3′UTR plasmid and a β-galactosidase 
plasmid in the absence (Dulbecco’s phosphate buffered 
saline – DPBS) or presence of 100 ng/mL prolactin or 
1nM 17β-estradiol for 72 hours. After 72 hours, cells were 
washed 2 times with DPBS and then lyzed in luciferase 
lysis buffer (Promega, Madison, USA). Following transfer 
of the lysate to a 96-well plate, the luciferin substrate 
(Promega, Madison, USA) was added. When examining 
the effect of signaling inhibitors, a shorter incubation 
period of 24 hours was utilized since prolonged use of 
signaling inhibitors is toxic to cells. For these assays, 
20,000 cancer cells were seeded per well in a 96-well plate 
and co-transfected with the construct and β-galactosidase 
plasmids in the presence of the inhibitors such as to 
incubate cells in 20 μM PD98059 (EMD Biosciences, 
La Jolla, USA), 1 μM wortmannin (EMD Biosciences, 
La Jolla, USA), 10 μM ICI-178280 (also known as 
Fulvestrant) (Sigma-Aldrich, St. Louis, USA) or 10 μM 
AG490 (EMD Biosciences, La Jolla, USA). Four hours 
after transfection, medium was changed to fresh medium 
with the same concentrations of inhibitors in the absence 
or presence of prolactin (100 ng/mL). Luciferase activity 
was measured 24 hours after initiation of transfection, 
but 20 hours after the addition of prolactin. Transfection 
efficiency was normalized to β-galactosidase expression. 
Control experiments using the standard in the kit 
demonstrated that none of the inhibitors directly affected 
luciferase activity. 
shRNA plasmid construction
The construction of shRNA was performed as 
described by [29], but in the suresilencing shRNA plasmid 
(SABioscience, Frederick, USA). The primers used for 
Figure 6: Model of the deduced pathway leading to tumor progression. Prolactin or estradiol activate Akt and MAPK 
signaling pathways via their membrane receptors. This leads to activation of ERα. Alternatively or additionally, ERα may be activated 
directly through the classical intracellular pathway. Once ERα is activated by one or both hormones, expression of miR-106b is increased. 
Increased expression of miR-106b facilitates cell proliferation through a decrease in p21 and increases cell migration through upregulation 
of messenchymal gene expression. 
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miR-106b shRNA construction are listed in Table 2. 
The outcome of increased expression of miR-106b was 
measured by p21 mRNA expression using real time PCR 
(primers in Table 2) and by the luciferase-p21 3′UTR 
assay described in 4.2.
Cell migration and epithelial-to-mesenchymal 
transition (EMT)
One hundred thousand cancer cells, transfected 
with control shRNA or miR-106b shRNA were placed 
in a constrained area around the center of well. After 
72 hours of incubation, cells were fixed with methanol for 
5 min, followed by staining with 0.03% methylene blue 
for 10 min. Cell movement was analyzed by comparing 
cell distribution between control shRNA- and shRNA-
miR106-treated cells. EMT status was examined by the 
expression of the mesenchymal genes, snail2, fibronectin, 
twist2 and vimentin using real-time PCR. Gene expression 
was normalized to the housekeeping genes, GAPDH and 
β-actin. All primer information is listed in Table 2. 
MTS relative cell number assay
Ten thousand cancer cells were seeded in each well 
of a 96-well plate and transfected with miR-106b shRNA 
or control plasmid. Relative cell number was assessed 
using a mitochondrial tetrazolium reduction assay (MTS, 
Promega, Madison, USA) at 72 hours. 
miRNA array
Human T47D cells were seeded in 35mm wells 
in the presence of vehicle, 100 ng/mL prolactin or 
S179DPRL for 72 hours. Cells were then collected for 
miRNA expression analysis following the instructions 
in the Signosis Human microRNA Array II (AP-0002) 
(Signosis, Santa Clara, USA).
Statistical analyses
All experiments were conducted a minimum of 3 
times using a minimum of triplicates on each occasion. 
Statistical significance was determined by ANOVA 
with post tests and Bonferroni corrections for multiple 
comparisons, where applicable. A P value < 0.05 was 
considered significant.
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Table 2: Primers used for cloning or PCR
miR-106b 
shRNA
F: CTTCCTGTCATAAAGTGCTGACAGTGCAGATCTGCAGTCTGGAGTTTCA
R: TGACAGGAAGTAAAGTGCTGACAGTGCAGATCGAGATCTTGGGCCTCT
p21 3′UTR F: CGACGCGTCCGCCCACAGGAAG
R: CCAAGCTTGAGCACCTGCTGTA
p21 F: CGACTGTGATGCGCTAATGG
R: GGCGTTTGGAGTGGTAGAAATC
Vimentin F: GGACCAGCTAACCAACGACA
R: AAGGTCAAGACGTGCCAGAG
Fibronectin F: ACAAGCATGTCTCTCTGCCA
R: TTTGCATCTTGGTTGGCTGC
Snail2 F: CAACGCCTCCAAAAAGCCAA
R: ACTCACTCGCCCCAAAGATG
Twist2 F: CAGAGCGACGAGATGGACAA
R: TGCATCCCAATTCCACTTGC
GAPDH F: CCTCCTGTTCGACAGTCAGC
R: TGGAATTTGCCATGGGTGGA
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